Abstract: A vehicle seat reinforcement device includes a leg portion mounted on a floor panel, a seat cushion frame slidably mounted on the leg portion, and a load reinforcing structure connected between the leg portion and the seat cushion frame, wherein when a seat belt anchorage load is transferred to the seat cushion frame, the seat cushion frame is locked to the leg portion by the load reinforcing structure.

Abstract: The present invention provides a method for preventing or treating a liver disease selected from the group consisting of non-alcoholic fatty liver, non-alcoholic steatohepatitis and hepatic fibrosis comprising administrating at least one selected from the group consisting of an Ssu72 peptide, a polynucleotide encoding the Ssu72 peptide, and an expression vector comprising the polynucleotide.

Abstract: Proposed is an all-solid-state battery including a self-standing sheet layer positioned on a negative electrode current collector. The all-solid-state battery may include the negative electrode current collector, the self-standing sheet layer positioned on the negative electrode current collector, a solid electrolyte layer positioned on the sheet layer, a positive electrode active material layer positioned on the solid electrolyte layer, and a positive electrode current collector positioned on the positive electrode active material layer. The sheet layer contains carbon nanotubes.

Abstract: Provided are a recombinant antigen comprising a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 and a SARS-CoV-2 antigen or a fragment thereof, a vaccine composition comprising the recombinant antigen, a gene construct comprising a polynucleotide encoding the recombinant antigen, a recombinant vector comprising the gene construct, a method for producing the SARS-CoV-2 recombinant antigen, and a kit for preventing or treating SARS-CoV-2 infection comprising the vaccine composition and users' instruction thereof, wherein the antigen exhibited higher immunogenicity against SARS-CoV-2 the neutralizing antibody was better formed in actual animal experiments, excellent protective immunity was induced, and toxicity did not appear in the toxicity test.

Abstract: The present invention relates to a transmembrane domain derived from human LRRC24 protein. More specifically, the present invention relates to a transmembrane domain derived from the human LRRC24 protein (LRRC24P transmembrane domain) or a cell-penetrating peptide, and an intracellular delivery system comprising same. The transmembrane domain derived from the human LRRC24 protein of the present invention can be used to deliver cargo materials such as compounds, biomolecules, and various polymer materials into cells. Since the LRRC24P transmembrane domain of the present invention exhibits higher cell penetration efficiency compared to conventional cell-penetrating peptides and is derived from human proteins, thus avoiding side effects and immune responses caused by peptides derived from foreign proteins, it can be usefully used as an effective intracellular delivery method for compounds, biomolecules, and various polymer materials applied to the human body.

Abstract: There may be provided a controller including an erase count monitor and a command generator. The erase count monitor may store and update an erase count value for the memory block. The erase count value may indicate a number of times an erase operation is performed for the memory block. The command generator may be configured to generate, based on the erase count value, a set command for setting a first select transistor among the select transistors to which an erase operation voltage is to be applied during the erase operation of the memory block, and a second select transistor among the select transistors to be floated when the erase operation voltage is to be applied to the first select transistor.

Abstract: There may be provided a controller including an erase count monitor and a command generator. The erase count monitor may store and update an erase count value for the memory block. The erase count value may indicate a number of times an erase operation is performed for the memory block. The command generator may be configured to generate, based on the erase count value, a set command for setting a first select transistor among the select transistors to which an erase operation voltage is to be applied during the erase operation of the memory block, and a second select transistor among the select transistors to be floated when the erase operation voltage is to be applied to the first select transistor.

Abstract: Provided herein may be a method of operating a memory device. The method may include applying an erase voltage to a memory block. The method may include performing an erase verify operation on the memory block. The method may include performing a first blind program operation based on a result of the erase verify operation.

Abstract: There may be provided a semiconductor memory device including a memory cell array, an erase count storage unit, and a control logic. The memory cell array may include a plurality of memory blocks. Each of the plurality of memory blocks may include a plurality of cell strings. The erase count storage unit may be configured to store an erase count value for each of the plurality of memory blocks. During an erase operation of a memory block, the erase operation may be performed based on the erase count value.

Abstract: An electronic device is provided, which uses magnetic force to couple to an external device. The electronic device includes a housing, a magnet positioned within the housing, and an elastic body connected to the magnet. At least a portion of the elastic body changes a shape or a position thereof, in response to a change of a magnetic force of the magnet.

Abstract: Provided herein may be a method of operating a memory device. The method may include applying an erase voltage to a memory block. The method may include performing an erase verify operation on the memory block. The method may include performing a first blind program operation based on a result of the erase verify operation.

Abstract: There may be provided a semiconductor memory device including a memory cell array, an erase count storage unit, and a control logic. The memory cell array may include a plurality of memory blocks. Each of the plurality of memory blocks may include a plurality of cell strings. The erase count storage unit may be configured to store an erase count value for each of the plurality of memory blocks. During an erase operation of a memory block, the erase operation may be performed based on the erase count value.

Abstract: The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media.

Abstract: Disclosed are novel indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

Abstract: Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

Abstract: The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media.

Abstract: An electronic device is provided. The electronic device includes a main unit including a first top surface, a first bottom surface opposite to the first top surface, and a first side surface configured to connect the first top surface and the first bottom surface, and at least one module unit including a second top surface, a second bottom surface opposite to the second top surface, and a second side surface configured to connect the second top surface and the second bottom surface. The module unit may be configured to couple to and uncouple from the main unit or another module unit in a state where one of the second top surface, the second bottom surface, and the second side surface faces one of the first top surface, the first bottom surface, and the first side surface. When the module unit is coupled to the main unit, the module unit may be electrically connected with the main unit.

Abstract: The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media.

Abstract: A heat dissipating apparatus and an electronic device having the same are provided. The electronic device includes a body, an internal circuit board provided in the body and including at least one heat generating element, and a heat diffusion type heat dissipating module provided in the body and stacked on a surface of the internal circuit board, so as to diffuse heat generated by the heat generating element toward a low temperature region having a temperature lower than a temperature of the at least one heat generating unit. The heat diffusion type heat dissipating module has a sheet shape which extends from the heat generating element toward a circumference surface of an inside of the body so that the heat is transferred from the heat generating element to the low temperature region.

Abstract: A semiconductor device and a manufacturing method thereof are provided. A semiconductor device includes a stack structure including conductive layers stacked in a step shape, a first interlayer insulating layer formed over the stack structure, the first interlayer insulating layer including contact holes with a uniform depth, which expose the conductive layers, lower contact plugs formed in the contact holes, the lower contact plugs being respectively contacted with the conductive layers, and lower contact pads respectively connected to the contact plugs.